Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sucralfate + oxetacaine is a fixed-dose combination oral medication used primarily for the treatment of gastric and duodenal ulcers, heartburn, hyperacidity, gastritis, esophagitis, and related gastrointestinal conditions. **Mechanism of Action:** Sucralfate acts as a gastroprotective agent by forming a physical barrier over ulcerated or damaged mucosal tissue in the stomach or duodenum. This protective layer shields the tissue from further injury by gastric acid, pepsin, and bile salts, thereby promoting healing. Oxetacaine (also known as oxethazaine) is a potent local anesthetic that provides rapid pain relief by numbing the mucosal lining at the site of ulceration or inflammation through reversible inhibition of sensory nerve conduction. The combination thus offers both mucosal protection (sucralfate) and symptomatic pain relief (oxetacaine). **Primary Indications:** Treatment of peptic ulcers (gastric/duodenal), heartburn, hyperacidity/indigestion, gastritis (including NSAID-induced), esophagitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sucralfate + oxetacaine.